The new cell line expands the company’s life science portfolio, which includes a Wnt Luciferase reporter as well as ALK Kinases, BCR-ABL Kinase, EGFR, PD-1 and PD-L1 cell lines, for a total of 16 off-the-shelf recombinant cell lines available for purchase.
CrownBio released the cell lines in conjunction with its in vivo grade isotype controls and diabetic and cancer tissue samples from relevant models.
According to Qian Shi, Vice President of Cancer Pharmacology and In Vitro Cancer Biology, the newly released stable cell lines cover important pathways in oncology such as CD137, CTLA-4, GITR, ICOS, OX40 and RANKL.
“Lead compounds targeting these pathways fill the pipelines of several major drug developers and biotech companies that are looking for solutions to rapidly screen their agents,” Shi told us.
“Providing cell lines that express these targets enable researchers to perform various potential studies including investigating their effect on cellular growth and screening compounds’ effectiveness against these targets.”
Shi explained that recombinant cell lines are amenable to the early stage of drug development, as they provide cost-effective models for quick results and insights into a potential therapeutic.
“The newly released cell lines will help formulate insightful data on lead compounds and move the right candidates to the next stage of drug development,” added Shi.
Last week, the company also launched a cell panel screening platform, OmniScreen. The new platform will be run on a cycled schedule every three months, which according to the company, provides a more cost-effective solution as it runs multiple compounds simultaneously on a fixed schedule.